We are live on ! Find out more
ONC icon

BeOne Medicines

199 hedge funds and large institutions have $6.8B invested in BeOne Medicines in 2019 Q1 according to their latest regulatory filings, with 32 funds opening new positions, 71 increasing their positions, 56 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

103% more capital inflows, than outflows

Capital inflows: $365M | Capital outflows: $180M

28% more first-time investments, than exits

New positions opened: 32 | Existing positions closed: 25

27% more repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 56

4% more funds holding

Funds holding: 192 → 199 (+7)

1.36% more ownership

Funds ownership: 46.58% → 47.94% (+1.4%)

17% less call options, than puts

Call options by funds: $9.8M | Put options by funds: $11.8M

36% less funds holding in top 10

Funds holding in top 10: 14 → 9 (-5)

Holders
199
Holders Change
+7
Holders Change %
+3.65%
% of All Funds
4.29%
Holding in Top 10
9
Holding in Top 10 Change
-5
Holding in Top 10 Change %
-35.71%
% of All Funds
0.19%
New
32
Increased
71
Reduced
56
Closed
25
Calls
$9.8​M
Puts
$11.8​M
Net Calls
-⁠$1.99​M
Net Calls Change
-⁠$31.6​M

ONC Hedge Fund Activity: Q1 2019 in Review

199 of the 4,635 institutional investors tracked by Wall St. Rank reported a position in BeOne Medicines (ONC) for Q1 2019, worth a combined $6.8B — up 2.1% from $6.66B a quarter earlier.

Buyers outnumbered sellers: 32 funds opened new ONC positions and 25 closed out — a net gain of 7 holders — while 71 added to existing stakes and 56 trimmed.

The largest buyer was Capital International Investors, adding an estimated $110M. The largest seller was Myriad Asset Management, exiting entirely with an estimated $23.3M sold.

  • 199 institutional investors held BeOne Medicines (ONC) as of Q1 2019, up from 192 in Q4 2018.
  • Funds reported $6.8B of BeOne Medicines stock for Q1 2019, up 2.1% quarter-over-quarter.
  • 32 funds opened new BeOne Medicines positions in Q1 2019 and 25 closed out, a net change of +7 holders.
  • The largest BeOne Medicines buyer in Q1 2019 was Capital International Investors, an estimated $110M added.
  • The largest BeOne Medicines seller in Q1 2019 was Myriad Asset Management, an estimated $23.3M sold.

Based on aggregated 13F filings for Q1 2019.